BioCatalystWatch
SCNIWorkspace / SCNI / OverviewCompany library
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. (SCNI)

Website

Price
Market cap
Next catalystExpected 2026SCN-1 · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

SCN-1

IL-17A × IL-17F

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SCN-1

IL-17A × IL-17F

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Anti-IL-17A/F NanoAbs

IL-17

PreINDP1P2P3FilingApproved
NanoAb

IL-17A × IL-17F

PreINDP1P2P3FilingApproved
inhaled COVID-19 NanoAb

PreINDP1P2P3FilingApproved
IL-17 NanoAb

IL-17A × IL-17F

PreINDP1P2P3FilingApproved
COVID-19 NanoAb

PreINDP1P2P3FilingApproved

History / paused

sFasL (Fas Ligand)

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing


PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SCNI SEC archive